Predicting Esophageal Cancer Borders Using PET-Imaging
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18+
SponsorUniversity Hospital Heidelberg
About this trial
The study examines the diagnostic precision of endosonography, mpMRI and PET/CT in defining tumor boundaries and tumor spread before and after neoadjuvant therapy and definitive surgery.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Histologically confirmed adenocarcinoma or squamous cell carcinoma of the esophagus, including AEG I and AEG II tumors in the primary situation
Planned surgical treatment of esophageal carcinoma
Possible staging advantage through FAPI PET/CT diagnostics
Patient information and written consent
Disqualifiers
Previous radiation therapy in the tumor region
Previous tumor disease with < 5 years of remission
Surgical therapy is not functionally or technically possible
Distant metastasis
Trial design
Design model
Parallel
Treatments tested in this trial
photon
Radiationradiation with 4-5 cm safte margin
surgical therapy
Procedure/Surgerysurgery based on PET-CT/MRI staging
Chemotherapy
Drugneoadjuvant chemotherapy
Treatment groups
30 Participants
are divided into 3 treatment groupsGroup A: Group 1, SurgeryOther 1 intervention
Group B: Group 2, Chemotherapy and surgeryOther 2 interventions
Group C: Group 3, chemotherapy, radiotherapy and surgeryOther 3 interventions
Trial outcomes
Primary outcomes
1
Tumor expansion
Number of patients with correlation of tumor expansion measured by histopathology and imaging techniques (Pet-CT)
Time frame
Before the start of therapy an immediately after the therapySponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov